## AGENDA
**Fifth Annual Scientific Retreat**  
February 27-28, 2013  
Washington, DC

### Tuesday, February 26th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30-5:30 pm</td>
<td>Registration open...</td>
<td>East Registration Desk</td>
</tr>
<tr>
<td>4:30-6:00 pm</td>
<td>Young Investigators Meeting (by invitation only).</td>
<td>Calvert Room</td>
</tr>
<tr>
<td>6:30-8:30 pm</td>
<td>Welcome Reception at the Embassy of Australia</td>
<td>Calvert Room</td>
</tr>
</tbody>
</table>

**Welcome:** Graham Fletcher, Deputy Chief of Mission, Embassy of Australia  
and Debra Black, MRA Co-founder and Chair of the Board

### Wednesday, February 27th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration open...</td>
<td>Blue Pre-function Room</td>
</tr>
<tr>
<td>7:00-8:00 am</td>
<td>Breakfast</td>
<td>Blue Pre-function Room</td>
</tr>
<tr>
<td>8:00-8:10</td>
<td>Opening Remarks</td>
<td>Blue Room</td>
</tr>
<tr>
<td>8:00-12:00</td>
<td>Session: Discovering New Melanoma Molecular Targets</td>
<td>Blue Room</td>
</tr>
</tbody>
</table>
| Chair: Martin McMahon, University of California, San Francisco  
8:10-8:35 | David Fisher, Massachusetts General Hospital: Pathways inducing melanoma formation and survival  
8:35-8:55 | Michael Davies, MD Anderson Cancer Center: Identifying therapeutic targets for melanoma brain metastases  
8:55-9:15 | Eva Hernando, New York University: Epigenetic differentiation therapy for melanoma  
9:15-9:35 | Sohail Tavazoie, Rockefeller University: Therapeutic targeting of novel metastatic microRNAs in human melanoma  
9:35-9:45 | Levi Garraway: Highly recurrent TERT promoter mutations in melanoma  
9:45-10:00 | BREAK                    |                                   |
| 10:00-10:20 | Edwin Bremer, University Medical Center Groningen: Metastatic spread and outgrowth by MCSP-targeted therapy  
10:20-10:45 | Hermann Steller, Rockefeller University: Targeting XIAP for the treatment of melanoma  
10:45-11:05 | Kenneth Bradley, University of California, Los Angeles: Targeting tumor vasculature with anthrax toxin  
11:05-11:30 | Alan Spatz, Jewish General Hospital/Lady Davis Institute for Medical Research: Role of the X chromosome in melanoma biology and prognosis  
11:30-11:45 | |                                   |
Wednesday, February 27th (cont.)

11:30-11:45 Jeff Trent, Translational Genomics Institute, and Pat LoRusso, Barbara Ann Karmanos Cancer Institute: Dream Team Overview: Personalized medicine for patients with metastatic BRAF wild type melanoma

11:45-12:00 Commentary by the Chair: The post-BRAF era of melanoma molecular targets

12:00-12:20 pm Keynote Address
Howard Koh, Assistant Secretary for Health,
U.S. Department of Health Human Services

12:30-1:40 pm Lunch
Discussion with Margaret Hamburg, Commissioner, U.S. Food and Drug Administration and Christopher Austin, Director, National Center for Advancing Translational Sciences, U.S. National Institutes of Health
Moderated by Michael Milken, Chairman, the Milken Institute and MRA Board Member

1:45-2:10 pm Special Lecture
Françoise Bernerd, L’Oreal Research and Innovation: Skin photocarcinogenesis from early molecular events to prevention strategies: a key role of human in vitro skin models

2:10-5:25 pm Session: Melanoma Immunotherapy
Chair: Thomas Gajewski, University of Chicago

2:10-2:30 Susan Kaech, Yale University: Regulatory macrophages: A new therapeutic target in melanoma

2:30-2:55 Drew Pardoll, Johns Hopkins University: The PD-1 pathway as a target for melanoma therapy: Biomarkers of response

2:55-3:20 Jennifer Wargo, Massachusetts General Hospital: Evidence for potential synergy of BRAF inhibition and immunotherapy in metastatic melanoma

3:20-3:45 Timothy Bullock, University of Virginia: Enhancing melanoma specific T cell function by CD27 stimulation

3:45-4:05 BREAK

4:05-4:25 Alexander Lesokhin, Memorial Sloan-Kettering Cancer Center: Myeloid derived suppressor cells and immunotherapy outcomes in melanoma

4:25-4:45 Guangyong Peng, St. Louis University: Novel strategies targeting Treg cell suppression for melanoma immunotherapy

4:45-5:10 David Kranz, University of Illinois at Urbana-Champaign: Optimal T cell receptor affinity for adoptive T cell therapy of melanoma

5:10-5:25 Commentary by the Chair: Targeting of immunoregulatory pathways in the clinic

5:25-5:30 pm Closing Remarks: Laura Brockway-Lunardi, MRA Scientific Program Director

6:15-9:00 pm Reception and Dinner
Keynote Speaker: Michael Milken, Chairman, the Milken Institute and MRA Board Member
Thursday, February 28th

6:30 am  Registration open .................................................................................. Blue Pre-function Room

7:00-8:15 am  Industry Roundtable Breakfast (by invitation only) ......................... Hampton Ballroom
7:00-8:15 am  General Breakfast ............................................................................ Blue Pre-function Room

8:30-11:35 am  Session: Drug Resistance and Combination Therapies .................. Blue Room
  Chair: David Solit, Memorial Sloan-Kettering Cancer Center
  8:30-8:50 Roger Lo, University of California, Los Angeles: Innate and acquired BRAF inhibitor resistance
  8:50-9:15 Thomas Graeber, University of California, Los Angeles: Delineating BRAF inhibitor resistance mechanisms using proteomic profiling
  9:15-9:35 Aaron Mackey, University of Virginia: Markers and mechanisms of melanoma resistance to combination chemotherapy
  9:35-9:55 Maria Wei, University of California, San Francisco: Targeting protein trafficking in melanoma combinatorial therapy
  9:55-10:20 Marcus Bosenberg, Yale University: Development of effective targeted and immune combination therapies
  10:20-10:35 BREAK
  10:35-11:00 Ze’ev Ronai, Sanford Burnham Research Institute: AGC kinases in melanoma development - implication for novel therapies
  11:00-11:25 Douglas Tyler, Duke University: Defining tumor-host interactions in regional advanced melanoma
  11:25-11:40 Commentary by the Chair: Developing rational combination therapy approaches for melanoma

11:40 am - 12:30 pm  Panel Discussion: Clinical Care Decision-Making for Today’s Melanoma Patients
  Chair: Michael Atkins, Georgetown University
  Panelists:
  • Keith Flaherty, Massachusetts General Hospital
  • John Kirkwood, University of Pittsburgh
  • Kim Margolin, University of Washington/Seattle Cancer Center
  • Antoni Ribas, University of California, Los Angeles
  • Caroline Robert, Institute Gustave-Roussy

12:30 pm  Closing Remarks: Suzanne Topalian, Chair, MRA Scientific Advisory Panel, and
Louise Perkins, MRA Chief Science Officer

12:30-1:30 pm  Lunch .................................................................................................... Hampton Ballroom

www.curemelanoma.org